LATE PRESENTATION PREDICTS ENDOCRINE DYSFUNCTION IN PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS (LCH) - A RETROSPECTIVE ANALYSIS OF THE WEST OF SCOTLAND LCH SERVICE 1998-2012

被引：0
|
作者：
Ronghe, M. [1 ]
Coyte, A. [1 ]
Murphy, D. [1 ]
Sastry, J. [1 ]
Ahmed, F. [1 ]
Shaikh, G. [1 ]
机构：
[1] Royal Hosp Sick Children Yorkhill, Glasgow, Lanark, Scotland
来源：
PEDIATRIC BLOOD & CANCER | 2014年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-195
引用
收藏
页码：S298 / S298
页数：1
相关论文
共 8 条
  • [1] Retrospective Analysis of Clofarabine Salvage Therapy in Refractory Multifocal Langerhans Cell Histiocytosis (LCH)
    Parekh, Deevyashali
    Lin, Howard
    McClain, Kenneth L.
    Gulati, Nitya
    Eckstein, Olive S.
    El-Mallawany, Nader Kim
    Agrusa, Jennifer Elise
    Allen, Carl E.
    [J]. BLOOD, 2023, 142
  • [2] THE IMPACT OF GASTRO-INTESTINAL INVOLVEMENT AT DIAGNOSIS ON OVERALL SURVIVAL IN PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS (LCH) - A RETROSPECTIVE ANALYSIS OF DAL-HX, LCH-I, LCH-II, AND LCH-III
    Potschger, Ulrike
    Thiem, Elfriede
    Arico, Maurizio
    Astigarraga, Itziar
    Braier, Jorge
    Donadieu, Jean
    Grois, Nicole
    Gadner, Helmut
    Henter, Jan-Inge
    Janka-Schaub, G.
    McClain, Ken
    Weitzman, Sheila
    Windebank, Kevin
    Minkov, Milen
    van den Bos, Cor
    Abla, Oussama
    [J]. PEDIATRIC BLOOD & CANCER, 2020, 67 : S25 - S25
  • [3] Analysis of soluble CD154 (sCD154) in the sera of patients with Langerhans cell histiocytosis (LCH)
    Ishii, R
    Morimoto, A
    Ikushima, S
    Inaba, T
    Sugimoto, T
    Imashuku, S
    [J]. PEDIATRIC BLOOD & CANCER, 2004, 43 (02) : 203 - 203
  • [4] Lenalidomide is a highly effective treatment option in patients with Langerhans cell histiocytosis (LCH) without severe side effects. Presentation of two cases
    Burchardt, C. A.
    Rummel, M. J.
    [J]. ONKOLOGIE, 2013, 36 : 11 - 11
  • [5] FACTORS ASSOCIATED WITH SHORT-TERM OUTCOME IN PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS - A RETROSPECTIVE ANALYSIS OF THE DAL-HX, LCH I-III STUDY COHORTS
    Potschger, Ulrike
    Abla, Oussama
    Astigarraga, Itziar
    Braier, Jorge
    Donadieu, Jean
    Henter, Jan-Inge
    Lehrnbecher, Thomas
    Rodriguez-Galindo, Carlos
    Sieni, Elena
    Thiem, Elfriede
    Nanduri, Vasanta
    van den Bos, Cor
    Minkov, Milen
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S37 - S38
  • [6] 2-Cda and Ara-C combined chemotherapy as a rescue for pediatric patients with refractory langerhans cell histiocytosis (LCH) and hematological dysfunction.
    Bernard, F
    Thomas, C
    Bertrand, Y
    Parker, JL
    Ouache, M
    Chastagner, P
    Perel, Y
    Vermylen, C
    Donadieu, J
    [J]. BLOOD, 2003, 102 (11) : 403A - 403A
  • [7] Impact of reactivation on the long-term outcome of multi-system Langerhans cell histiocytosis (LCH) patients: Analysis of JLSG-96 protocol study
    Morimoto, Akira
    Ikushima, Satoshi
    Kinugawa, Naoko
    Ishii, Eiichi
    Kohdera, Urara
    Sako, Masahiro
    Fujimoto, Junichiro
    Bessho, Fumio
    Horibe, Keizo
    Tsunematsu, Yukiko
    Imashuku, Shinsaku
    [J]. PEDIATRIC BLOOD & CANCER, 2007, 48 (07) : 758 - 759
  • [8] Concurrent enhancer of Zeste homolog 2 (EZH2) over-expression with BRAFV600E mutation predicts a poor outcome in patients with Langerhans cell histiocytosis (LCH): A pilot study
    Saha, Aditi
    Whiting, Junmin
    Kim, Jongphil
    Sanjay, Felix
    Chen, Lugen
    Qin, Dahui
    Zhang, Ling
    Sokol, Lubomir
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1